Skip to main content
Granules India Ltd. logo

Granules India Ltd. — Investor Relations & Filings

Ticker · GRANULES ISIN · INE101D01020 LEI · 335800HJF1KE335ASX37 BSE.NS Manufacturing
Open in API
Filings indexed 954 across all filing types
Latest filing 2025-02-27 Regulatory Filings
Country IN India
Listing BSE.NS GRANULES

About Granules India Ltd.

https://granulesindia.com/

Granules India Ltd. is a vertically integrated manufacturer specializing in Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). The organization maintains a significant global presence through the large-scale production of essential molecules, including Paracetamol, Ibuprofen, Metformin, Methocarbamol, and Guaifenesin. Its business model emphasizes a complete value chain approach, from core chemical synthesis to final product packaging, ensuring operational efficiency and supply chain security. The company serves a diverse international clientele across more than 75 countries, utilizing advanced manufacturing facilities that comply with global regulatory standards. Key strengths include high-volume production capabilities, cost leadership, and a focus on delivering consistent quality in high-demand therapeutic areas.

Recent filings

Filing Released Lang Actions
General Updates
Regulatory Filings Classification · 100% confidence The document text is extremely short (127 characters) and contains only a digital signature with no substantive content, financial data, or report information. It does not contain any report, announcement, or detailed information. Given the lack of content, this is likely a regulatory filing or a certification-type document with no report attached. According to the rules, such minimal content defaults to Regulatory Filings (RNS).
2025-02-27 English
Press Release
M&A Activity Classification · 95% confidence The document is a press release announcing Granules India's acquisition of Senn Chemicals AG, detailing the strategic rationale, business segments, and advisors involved. It is dated February 21, 2025, and addressed to stock exchanges for dissemination. The content focuses on a corporate transaction (acquisition) and business expansion into peptide therapeutics and CDMO segments. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is not a full report but an announcement of a significant corporate event related to merger and acquisition activity. Therefore, the appropriate classification is 'M&A Activity' (TAR). The document length (7804 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2025-02-21 English
Outcome of Board Meeting
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Granules India Limited to stock exchanges regarding the outcome of a board meeting held on February 21, 2025. The key content includes approval of the acquisition of 100% equity stake in Senn Chemicals AG, a Switzerland-based company, and the incorporation of a wholly owned subsidiary in India for this acquisition. The document references compliance with SEBI Listing Regulations and provides detailed disclosures about the acquisition and subsidiary incorporation in annexures. There are no financial statements, quarterly or annual results, or detailed financial performance data. The document is primarily an announcement of a material event (acquisition and subsidiary incorporation) as required by stock exchange regulations. It does not contain a full report, audit, or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as acquisitions and subsidiary incorporations.
2025-02-21 English
General Updates
Environmental & Social Information Classification · 95% confidence The document is a short announcement dated February 7, 2025, informing stock exchanges about Granules India Limited's updated CDP (Carbon Disclosure Project) Climate Rating. It highlights the company's improved environmental rating from 'C' to 'B' and explains the CDP rating categories. The document is brief (1986 characters) and serves as an update on environmental and sustainability performance rather than a detailed report. It does not contain financial data or comprehensive ESG reporting but focuses on environmental rating information. Therefore, it fits best under Environmental & Social Information (SR) category, which covers reports detailing the company's performance on Environmental, Social, and Governance factors.
2025-02-07 English
Resignation
Regulatory Filings
2025-02-03 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release dated January 30, 2025, announcing FDA approval for a pharmaceutical product by Granules India Limited. It is addressed to stock exchanges and intended for public dissemination. The content focuses on a specific product approval and company update rather than financial results, management changes, or regulatory filings. The document length is 3895 characters, which is relatively short and typical for a press release. There is no detailed financial data, no mention of annual or quarterly reports, no voting results, no legal proceedings, and no executive compensation details. The document is clearly a press release announcing a significant company event related to product approval and business development. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to company business updates impacting capital markets and investor information.
2025-01-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.